It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...
The survival prognosis for patients with chronic phase CML has greatly improved since the introduction of TKIs, with some studies showing life expectancy close to the general population. Nonetheless, ...
After being diagnosed with chronic myeloid leukemia, graphic designer Aaron von Freter was able to participate in a clinical trial that offered him hope of being cured. When Aaron von Freter learned ...
Genetic testing for chronic myeloid leukemia (CML) can tell doctors if someone has leukemia, what type they may have, and whether treatment is working. The tests look for atypical changes in certain ...
Chronic myeloid leukemia (CML) is a hematopoietic malignancy characterized by BCR-ABL1 gene fusion. The immune microenvironment, implicated in relapse and drug resistance, poses significant challenges ...
Tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment, offering more effective and better-tolerated options than previous therapies. Second- and third-generation TKIs address resistance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results